Cocrystal Pharma Grants Stock Options to Directors and Executives Under New Equity Plan
I'm PortAI, I can summarize articles.
Cocrystal Pharma Inc. has approved new compensation terms for its directors and executives, effective January 9, 2026. The Compensation Committee granted non-qualified stock options under the 2025 Equity Incentive Plan, with a 10-year term and an exercise price based on the closing price on January 8, 2026. Options will vest in two parts: half on January 9, 2027, and the rest in quarterly installments starting March 31, 2027. Dr. Roger Kornberg and Dr. Philip Frost received 24,615 stock options each, with Dr. Kornberg also awarded a $50,000 cash payment for his advisory role.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments